Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotoxicity. However. early and late hematological toxicity has emerged as a substantial clinical hurdle leading among others to an increased r... https://www.markbroyard.com/hot-save-turbo-air-m3f24-1-n-29-wide-m3-series-reach-in-freezer-featuring-one-solid-door-energy-star-on-sale-top-super/